Physitrack Q2 2025: Continued margin expansion and cash flow uplift - Redeye

Physitrack’s Q2 2025 results came in broadly in line with our expectations. The key highlights of the report are the continued improvement in margins, both year-over-year and sequentially, alongside a significant uplift in cash flow. EBITDAC improved 4pp from Q1 and marked the 15% threshold — a milestone we view as strategically important for the company’s margin trajectory. Given the overall alignment with our forecasts, we anticipate only minor revisions to our estimates

Länk till analysen i sin helhet: https://www.redeye.se/research/1120399/physitrack-q2-2025-continued-margin-expansion-and-cash-flow-uplift?utm_source=finwire&utm_medium=RSS